Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment

Detalles Bibliográficos
Autores principales: Vellas, Camille, Kamar, Nassim, Izopet, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307285/
https://www.ncbi.nlm.nih.gov/pubmed/35878684
http://dx.doi.org/10.1016/j.jinf.2022.07.014
_version_ 1784752724124893184
author Vellas, Camille
Kamar, Nassim
Izopet, Jacques
author_facet Vellas, Camille
Kamar, Nassim
Izopet, Jacques
author_sort Vellas, Camille
collection PubMed
description
format Online
Article
Text
id pubmed-9307285
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The British Infection Association. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-93072852022-07-25 Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment Vellas, Camille Kamar, Nassim Izopet, Jacques J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-11 2022-07-22 /pmc/articles/PMC9307285/ /pubmed/35878684 http://dx.doi.org/10.1016/j.jinf.2022.07.014 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Vellas, Camille
Kamar, Nassim
Izopet, Jacques
Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
title Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
title_full Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
title_fullStr Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
title_full_unstemmed Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
title_short Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
title_sort resistance mutations in sars-cov-2 omicron variant after tixagevimab-cilgavimab treatment
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307285/
https://www.ncbi.nlm.nih.gov/pubmed/35878684
http://dx.doi.org/10.1016/j.jinf.2022.07.014
work_keys_str_mv AT vellascamille resistancemutationsinsarscov2omicronvariantaftertixagevimabcilgavimabtreatment
AT kamarnassim resistancemutationsinsarscov2omicronvariantaftertixagevimabcilgavimabtreatment
AT izopetjacques resistancemutationsinsarscov2omicronvariantaftertixagevimabcilgavimabtreatment

Ejemplares similares